← Leaderboards
Jan M Bruder
University Of Texas Hlth Sci Ctr San Ant
$2,532,688
Attributed
$2,532,688
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $127.5K · FY2005–07$200K$150K$100K$50K$0
'05
'06
'07
Funding mix
By agency
NIH$2,532,688 · 9
By mechanism
M01$2,532,688 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- G David Roodman$13,528,230
- Gregory R Mundy$7,763,862
- Theresa A Guise$8,674,181
- Natalie Callander$852,839
- Anthony W Tolcher$2,350,887
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectBone DensityPathologic Bone ResorptionLongitudinal Human StudyOsteoporosisBone FractureMaleProstate NeoplasmsAlendronateHuman Therapy EvaluationWomen'S HealthPatient /Disease RegistryPhysiologic Bone ResorptionOutcomes ResearchPrognosisOsteitis DeformansDisease /Disorder Proneness /RiskMale CastrationOsteoclastsMeasles VirusNeoplasm /Cancer SurgeryInterleukin 6Diphosphonate
Grant awards (20)
GENETICS OF BONE DENSITY IN MEXICAN AMERICANS - CONTINUATION$32,417
M01 · FY2007 · RR · contact PI
GENETICS OF BONE DENSITY IN MEXICAN AMERICANS - CONTINUATION$79,832
M01 · FY2006 · RR · contact PI
PREVENTION OF BONE LOSS WITH ALENDRONATE IN PROSTATE CANCER WITH HORMONE DEPRIVA$446
M01 · FY2006 · RR · contact PI
GENETICS OF BONE DENSITY IN MEXICAN AMERICANS - CONTINUATION$125,084
M01 · FY2005 · RR
PREVENTION OF BONE LOSS WITH ALENDRONATE IN PROSTATE CANCER WITH HORMONE DEPRIVA$2,397
M01 · FY2005 · RR
Genetics of Bone Density in Mexican Americans$108,066
M01 · FY2004 · RR
Acculturation/Diet/Workload Effect on Bone Density in MA$15,541
M01 · FY2004 · RR
Alendronate Therapy for Bone Loss in Prostate Cancer$6,145
M01 · FY2004 · RR
EFFECT OF ANTIRESORPTIVES IN PATIENTS W/ PAGETS DISEASE$234,837
M01 · FY2002 · RR
DETERMINATION OF RATE OF BONE LOSS IN MEN UNDERGOING CASTRATION FOR CANCER$234,837
M01 · FY2002 · RR
DETERMINATION OF RATE OF BONE LOSS IN MEN UNDERGOING CASTRATION FOR CANCER$234,837
M01 · FY2002 · RR
NATIONAL OSTEOPOROSIS RISK ASSESSMENT$234,837
M01 · FY2002 · RR
NATIONAL OSTEOPOROSIS RISK ASSESSMENT$234,837
M01 · FY2002 · RR
EFFECT OF ANTIRESORPTIVES IN PATIENTS W/ PAGETS DISEASE$234,837
M01 · FY2002 · RR
EFFECT OF ANTIRESORPTIVES IN PATIENTS W/ PAGETS DISEASE$234,837
M01 · FY2001 · RR
NATIONAL OSTEOPOROSIS RISK ASSESSMENT$234,837
M01 · FY2001 · RR
DETERMINATION OF RATE OF BONE LOSS IN MEN UNDERGOING CASTRATION FOR CANCER$234,837
M01 · FY2001 · RR
DETERMINATION OF RATE OF BONE LOSS IN MEN UNDERGOING CASTRATION FOR CANCER$16,409
M01 · FY2000 · RR
EFFECT OF ANTIRESORPTIVES IN PATIENTS W/ PAGETS DISEASE$16,409
M01 · FY2000 · RR
NATIONAL OSTEOPOROSIS RISK ASSESSMENT$16,409
M01 · FY2000 · RR